	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	182.96	240.96	304.39	356.31	402.91	433.20	494.62	588.86	526.67	571.88	687.35	829.04
Cost of Operating Revenue	68.69	88.59	99.47	115.07	136.70	150.47	195.38	206.36	205.35	217.77	252.55	285.56
Gross Profit	114.26	152.37	204.91	241.24	266.21	282.73	299.24	382.50	321.32	354.11	434.80	543.48
Gross Margin	62.5	63.2	67.3	67.7	66.1	65.3	60.5	65.0	61.0	61.9	63.3	65.6
Total Operating Expenses	123.43	165.70	207.07	230.98	274.82	292.59	353.50	387.84	444.53	480.50	552.25	625.55
Operating Profit	59.52	75.26	97.32	125.33	128.09	140.61	141.12	201.02	82.14	91.38	135.10	203.49
Operating Margin	32.5	31.2	32.0	35.2	31.8	32.5	28.5	34.1	15.6	16.0	19.7	24.5
Financing Income/(Expense) - Net	6.55	4.40	5.88	3.36	4.01	3.66	3.46	3.56	4.40	4.28	8.12	8.24
Profit before Taxes	67.62	81.80	81.67	144.99	138.06	140.42	152.47	227.72	88.59	95.98	145.44	212.88
Income Taxes	23.58	30.00	38.83	51.72	52.92	52.01	39.32	51.58	24.23	26.49	54.69	50.03
Profit after Tax	45.22	51.80	42.84	93.28	85.14	88.41	113.15	176.14	64.49	70.76	91.51	163.04
PAT Margin	24.7	21.5	14.1	26.2	21.1	20.4	22.9	29.9	12.2	12.4	13.3	19.7
EPS - Basic - ex Extraordinary Items	3.05	3.35	2.67	5.79	5.32	5.58	7.14	11.10	4.06	4.46	5.76	10.24
EPS - Diluted - ex Extraordinary Items	3.05	3.35	2.66	5.77	5.30	5.57	7.12	11.08	4.06	4.45	5.74	10.21
EBIT	59.52	75.26	97.32	125.33	128.09	140.61	141.12	201.02	82.14	91.38	135.10	203.49
EBITDA	72.39	93.50	115.37	145.43	154.26	172.52	171.40	234.89	120.85	138.39	190.36	262.07
EBITDA Margin	39.6	38.8	37.9	40.8	38.3	39.8	34.7	39.9	22.9	24.2	27.7	31.6

Balance Sheet

Abridged

Understanding Balance Sheet

Thyrocare Technologies Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	110.67	136.66	149.53	142.39	136.02	152.25	238.13	270.02	272.94	278.51	337.72	372.29
Long-Term Investments	1.61	-	-	-	-	2.82	3.08	9.05	6.29	5.22	7.89	6.66
Property Plant & Equipment - Net	154.63	152.38	168.62	190.18	187.25	172.58	160.08	186.79	194.43	203.71	198.31	208.68
Total Non-Current Assets	218.55	274.45	288.29	336.59	338.70	317.08	307.67	337.64	359.78	365.37	355.03	374.93
Total Assets	329.22	411.11	437.83	478.99	474.72	469.33	545.80	607.66	632.72	643.88	692.75	747.22
Total Current Liabilities	7.30	15.21	17.62	20.29	20.59	81.69	95.10	64.52	77.10	90.48	121.84	109.91
Long Term Debt	-	5.50	7.25	10.08	2.50	8.19	5.45	15.70	16.12	22.71	16.92	39.18
Total Non-Current Liabilities	9.54	12.32	12.40	15.41	19.01	20.98	23.42	16.57	20.40	25.77	23.86	51.29
Total Liabilities	16.84	27.53	30.02	35.70	39.60	102.67	118.52	81.09	97.50	116.25	145.70	161.20
Total Shareholders' Equity	276.37	383.57	407.81	443.29	435.12	366.66	427.28	526.57	534.30	526.77	546.75	585.50
Minority Interest	36.01	-	-	-	-	-	-	-	0.92	0.86	0.30	0.52
Total Equity	312.38	383.57	407.81	443.29	435.12	366.66	427.28	526.57	535.22	527.63	547.05	586.02
Total Liabilities & Equity	329.22	411.11	437.83	478.99	474.72	469.33	545.80	607.66	632.72	643.88	692.75	747.22

Cash Flow

Abridged

Understanding Cash Flow Statement

Thyrocare Technologies Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	52.96	63.13	80.76	98.52	97.15	106.88	133.62	188.61	122.57	131.81	177.68	222.00
Working Capital - Increase/(Decrease)	-16.86	0.87	5.57	2.28	-0.58	33.52	-17.90	-79.22	5.79	30.16	12.54	-8.46
Net CF from Operating Activities	36.10	63.99	86.33	100.80	96.57	140.40	115.72	109.39	128.36	161.97	190.22	213.54
Capital Expenditures - Net	9.92	14.34	36.31	43.64	38.91	9.88	22.95	14.90	41.55	60.86	44.88	20.88
Net CF from Investing Activities	-23.49	-20.92	-46.50	-47.14	-13.38	-0.29	-50.60	-24.30	-40.29	-92.26	-54.49	-26.08
Dividends Paid - Cash - Total	18.99	37.90	40.29	53.72	26.86	131.96	52.84	79.31	79.35	95.27	95.31	148.43
Stock - Issuance/(Retirement) - Net	0.03	-	-	-	-62.96	0.04	0.03	0.03	0.03	0.02	0.04	-
Debt - LT & ST - Issuance/(Retirement) - Total	-	-	-	-	2.50	-4.39	-8.05	-5.38	-5.53	15.87	-32.08	-18.39
Net Cash Flow from Financing Activities	-18.96	-37.90	-40.29	-53.72	-88.10	-136.31	-60.88	-84.66	-83.93	-78.17	-127.35	-166.82
Free Cash Flow to Equity	26.18	49.65	50.02	57.17	60.16	126.13	84.72	89.11	81.28	116.98	113.26	174.27
Free Operating CF net dividend	7.12	11.67	9.67	3.43	29.46	-1.46	34.62	-7.75	5.36	5.12	50.02	44.23
Free Operating CF	26.11	49.57	49.96	57.15	56.32	130.50	87.46	71.56	84.71	100.39	145.33	192.66

Business Segment Analysis

FY End:

Mar 26

Thyrocare Technologies Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

Diagnostic Testing Services (93.2%)₹ 772.53 CrImaging Services (6.4%)₹ 53.14 CrOthers (0.4%)₹ 3.37 Cr

Assets

Diagnostic Testing Services (68.8%)₹ 514.08 CrImaging Services (25.7%)₹ 192.34 CrUnallocated (5.5%)₹ 40.80 Cr

Regional Segment Analysis

FY End:

Mar 26

Thyrocare Technologies Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (100.0%)₹ 829.04 Cr

Assets

India (100.0%)₹ 747.22 Cr

Historical Segment Analysis

Track how Thyrocare Technologies Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Business

Regional

Business

	2015 Mar 31	2016 Mar 31	2017 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Diagnostic Testing Services	17	16	8	20	14	39	40	21	47	53
Imaging Services	6	0	9	20	1	0	0	4	14	2

Frequently Asked Questions

What is the revenue of Thyrocare Technologies Ltd.?

The latest trailing twelve month revenue of Thyrocare Technologies Ltd. is ₹ 829.04 Cr, reflecting a 1-year growth of 20.61% and a 3-year CAGR of 16.33%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Thyrocare Technologies Ltd.?

The latest trailing twelve month net profit (PAT) of Thyrocare Technologies Ltd. is ₹ 163.04 Cr, with a 3-year earnings CAGR of 36.17%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Thyrocare Technologies Ltd.?

The trailing twelve month EBITDA of Thyrocare Technologies Ltd. is approximately ₹ 203.46 Cr (based on an operating margin of 24.54%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Thyrocare Technologies Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Thyrocare Technologies Ltd. is 10.24. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Thyrocare Technologies Ltd.?

The debt-to-equity ratio of Thyrocare Technologies Ltd. stands at 0.09. The interest coverage ratio is 72.66x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Thyrocare Technologies Ltd.?

The estimated book value per share of Thyrocare Technologies Ltd. is 36.68 (derived from a P/B ratio of 15.15 and market price of ₹ 555.60), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Thyrocare Technologies Ltd.?

The trailing twelve month operating cash flow of Thyrocare Technologies Ltd. is ₹ 213.54 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Thyrocare Technologies Ltd. report consolidated or standalone financials?

Thyrocare Technologies Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.